From yesterdays article on Energing Growth Usin
Post# of 147866
(Total Views: 513)
Posted On: 01/08/2021 9:18:20 AM
From yesterdays article on Energing Growth
Using simulation software to calculate the threshold where the number of deaths is statistically relevant the chart below shows the leronlimab arm of the study could have between 45 – 49 deaths and still be statistically relevant. This means that leronlimab could have as high as an 18.85% mortality rate and still meet the 28 day all-cause mortality endpoint. Currently the entire study which includes the placebo and leronlimab arm has 87 deaths (22.3% mortality) with 5 more days to go. Without the statistics package this is just an educated guess, but this is where the news of the 87 deaths represents an extremely positive development.
https://emerginggrowth.com/cytodyn-update-rev...3pqycLGofM
Using simulation software to calculate the threshold where the number of deaths is statistically relevant the chart below shows the leronlimab arm of the study could have between 45 – 49 deaths and still be statistically relevant. This means that leronlimab could have as high as an 18.85% mortality rate and still meet the 28 day all-cause mortality endpoint. Currently the entire study which includes the placebo and leronlimab arm has 87 deaths (22.3% mortality) with 5 more days to go. Without the statistics package this is just an educated guess, but this is where the news of the 87 deaths represents an extremely positive development.
https://emerginggrowth.com/cytodyn-update-rev...3pqycLGofM
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼